VCYT
VCYT
Indices, commodities, movers, heatmap, and top stories. No login required.
VCYT
VCYT NASDAQ
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?
Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell?
Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.